Eldecalcitol prevents muscle loss and osteoporosis in disuse muscle atrophy via NF-κB signaling in mice [PDF]
Skeletal Muscle, 2023 We investigated the effect of eldecalcitol on disuse muscle atrophy. C57BL/6J male mice aged 6 weeks were randomly assigned to control, tail suspension (TS), and TS-eldecalcitol–treated groups and were injected intraperitoneally twice a week with either ...
Haichao Zhang +7 more
doaj +3 more sources
Osteoporosis and Sarcopenia, 2021 Objectives: To compare the effect of eldecalcitol and alfacalcidol on skeletal microstructure by high-resolution peripheral QCT (HR-pQCT). Methods: This was a substudy of a randomized, double-blind, active comparator trial.
Xiaolin Ni, Juan Feng, Yan Jiang
exaly +4 more sources
Eldecalcitol prevents muscle loss by suppressing PI3K/AKT/FOXOs pathway in orchiectomized mice [PDF]
Frontiers in Pharmacology, 2022 Elderly male patients are susceptible to develop osteoporosis and sarcopenia, especially those with fragility fractures, hypogonadism, and prostate cancer with androgen deprivation therapy.
Minmin Chen, Qun Cheng, Du Yanping
exaly +4 more sources
A Case of Milk-Alkali Syndrome Caused by Diuretic-Induced Alkalosis and Polypharmacy [PDF]
Medicina, 2023 Milk-alkali syndrome, which is characterized by hypercalcemia, metabolic alkalosis, and renal dysfunction, typically results from the ingestion of large amounts of calcium and absorbable alkaline products.
Naoya Mizutani +2 more
doaj +3 more sources
The potential effect of romosozumab on perioperative management for instrumentation surgery [PDF]
JOR SpineBackground Age‐related changes in bone health increase the risk for complications in elderly patients undergoing orthopedic surgery. Osteoporosis is a key therapeutic target that needs to be addressed to ensure successful instrumentation surgery.
Koji Ishikawa +11 more
doaj +3 more sources
Renal Failure, 2019 Background: Eldecalcitol (ELD) is an active vitamin D3 analog that is widely used in Japan for the treatment of osteoporosis. The most common adverse drug reaction of ELD is hypercalcemia.
Shunsuke Yamada +2 more
exaly +3 more sources
Distribution effect of SOST on alveolar bone micro-bone formation in rats induced by Eldecalcitol [PDF]
European Journal of Medical ResearchObjectives This study controlled experimental and histological study based on an ovariectomized (OVX) rat model, and aimed to clarify the distribution changes of TRAP-positive osteoclasts and sclerostin-positive osteocytes in the alveolar septal area of ...
Ying Guo +5 more
doaj +2 more sources
Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis [PDF]
Frontiers in OncologyObjectivesThis network meta-analysis (NMA) aims to compare the efficacy of bone-protective interventions in preventing AIs-induced bone loss at lumbar spine and hip sites.MethodsWe systematically searched PubMed, Embase, Cochrane Library, Web of Science,
Yonghui Xu +4 more
doaj +2 more sources
Effects of active vitamin D analogues on muscle strength and falls in elderly people: an updated meta-analysis [PDF]
Frontiers in EndocrinologyBackgroundElderly people are at high risk of falls due to decreased muscle strength. So far, there is currently no officially approved medication for treating muscle strength loss.
An Xiong +11 more
doaj +2 more sources
Combined Use of Ibandronate and Eldecalcitol in Postmenopausal Japanese Women with Osteoporosis
Journal of Orthopaedic Surgery, 2016 Purpose To evaluate the effect of combined use of ibandronate and eldecalcitol for 6 to 12 months on bone mineral density (BMD) and bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis.
Junichi Takada +2 more
exaly +2 more sources